Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

TP53 is a tumor suppressor gene frequently mutated in human cancers and is generally
associated with poor outcomes. TP53 mutations are found in approximately 5% to 10% of …

Abstract The European LeukemiaNet (ELN) acute myeloid leukemia (AML) genetic risk
classification systems are based on response to intensive chemotherapy; their ability to …

TP53 is a tumor suppressor gene located on the short arm of chromosome 17 (p13), known
to be involved in multiple cellular processes and regulate cell proliferation by responding to …

Abstract The European LeukemiaNet (ELN) genetic risk classifications were developed
based on data from younger adults receiving intensive chemotherapy. Emerging analyses …

The clinical impact of molecular ontogeny in acute myeloid leukemia (AML) was defined in
patients treated with intensive chemotherapy. In a cohort of 314 newly diagnosed AML …

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in
newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and …

Dear Editor, Overall survival has developed well in hematological malignancies but among
the main entities, 5-year survival in acute myeloid leukemia (AML) has remained the lowest …

Venetoclax‐azacitidine is the standard of treatment for unfit acute myeloid leukemia patients.
In the VIALE‐A study, treatment was given until progression but there are no data on its …

Venetoclax (VEN) combined with hypomethylating agents (HMA) decitabine or azacitidine is
used for adult acute myeloid leukaemia (AML), but its application in paediatric, adolescent …